A Kenya guide to checking peptide-related product claims in the Pharmacy and Poisons Board product register and matching the responsible retail, wholesale, hospital, or manufacturing facility in the public licence register.
Kenyan search results can combine registered medicines, chemists, hospitals, wholesalers, clinics, social sellers, imported products, and laboratory materials. The PPB product register and facility register expose different identities, so one match cannot validate the complete offer.
Use this checklist to verify the local product, seller, and supply records before comparing price or availability.
Use the PPB public product register to match the registration number, trade name, active ingredient, dosage, pack size, registration date, local technical representative, marketing authorization holder, and current status for the exact presentation.
Use the PPB facilities register to search the retail, wholesale, hospital, or manufacturing establishment behind the offer. Match its legal name, business type, registration number, licence status, location, and detail record.
A product result does not establish that a website, chemist, clinic, courier, or marketplace account is the licensed facility in the record. Keep the legal entity and delivery claim attached while comparing availability or price.
Each answer is tied to the local records below so you can see what is confirmed, what remains unknown, and where to recheck it. Open the primary sources ↓
No blanket answer is supportable. Use the PPB public product register to match the registration number, trade name, active ingredient, dosage, pack size, registration date, local technical representative, marketing authorization holder, and current status for the exact presentation. In Kenya, begin with Public pharmaceutical products register from Kenya Pharmacy and Poisons Board; the product, seller, and supply route still need to resolve to the same current record.
No. Peptide Local withholds a commercial table for Kenya until seller category, local delivery, regulatory or research status, exact price, and observation date are all sourced. This page is a verification route, not a shopping recommendation.
For Kenya, start with Public pharmaceutical products register from Kenya Pharmacy and Poisons Board, then open Public facilities licence register from Kenya Pharmacy and Poisons Board. The records answer separate questions, so confirm each current entry instead of treating one match as proof of the seller, product, and route together.
Resolve the identity first, then use this country’s official product and seller records. A matching name never transfers approval, trial evidence, or seller authority.
KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.
Primary identity sourceFDA briefing document for KPV-related bulk drug substancesU.S. Food and Drug Administration ↗BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗TB-500 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗GHK-Cu is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Melanotan II is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗MOTS-c is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Tesamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceCheck the FDA Purple Book product recordU.S. Food and Drug Administration ↗AOD-9604 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Ipamorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗PT-141 / Bremelanotide is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the current DailyMed drug labelNational Library of Medicine, DailyMed ↗CJC-1295 no DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗CJC-1295 DAC is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Lilly states that retatrutide has not been approved by any regulatory agency, is not available for public use, and is legally available only through Lilly-sponsored clinical trials. A Kenya listing cannot inherit that clinical identity. The Pharmacy and Poisons Board product register and facilities licence register answer separate questions about an exact product and the entity offering it. Both records must match before interpreting a local offer.
Primary identity sourceTRIUMPH-1 Phase 3 study - NCT05929066ClinicalTrials.gov ↗Mazdutide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceGLORY-1 Phase 3 study - NCT05607680ClinicalTrials.gov ↗Ecnoglutide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSLIMMER Phase 3 study - NCT05813795ClinicalTrials.gov ↗Enicepatide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceCT388-103 Phase 2 study - NCT06525935ClinicalTrials.gov ↗Eloralintide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceEloralintide Phase 2 study - NCT06230523ClinicalTrials.gov ↗Cagrilintide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗Petrelintide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceZUPREME-1 Phase 2 study - NCT06662539ClinicalTrials.gov ↗CagriSema is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗MariTide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourcePhase 2 dose-ranging study - NCT05669599ClinicalTrials.gov ↗Survodutide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSYNCHRONIZE-1 Phase 3 study - NCT06066515ClinicalTrials.gov ↗VK2735 is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceVENTURE injectable Phase 2 study - NCT06068946ClinicalTrials.gov ↗Pemvidutide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceIMPACT Phase 2b MASH study - NCT05989711ClinicalTrials.gov ↗Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Kenya can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceAMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414ClinicalTrials.gov ↗Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.
Primary identity sourceCurrent ZEPBOUND prescribing informationNational Library of Medicine, DailyMed ↗Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.
Primary identity sourceCurrent FOUNDAYO prescribing informationNational Library of Medicine, DailyMed ↗Semaglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.
Primary identity sourceCurrent WEGOVY prescribing informationNational Library of Medicine, DailyMed ↗DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem substance recordNational Library of Medicine, PubChem ↗Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the current SCENESSE labelNational Library of Medicine, DailyMed ↗NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA orphan-drug recordU.S. Food and Drug Administration ↗Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Kenya. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.
Primary identity sourceCurrent EGRIFTA WR prescribing informationNational Library of Medicine, DailyMed ↗Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.
Primary identity sourceCurrent SAXENDA prescribing informationNational Library of Medicine, DailyMed ↗SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.
Primary identity sourceCurrent SCENESSE prescribing informationNational Library of Medicine, DailyMed ↗VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Kenya. Verify the exact local records below.
Primary identity sourceCurrent VYLEESI prescribing informationNational Library of Medicine, DailyMed ↗Peptide Local will not manufacture a ranking from thin data. A local table appears only after seller category, authorization or research status, delivery market, price, and source date can all be stated clearly.
Official sources are linked directly. Open them to confirm the current record; this page is a guide, not a substitute for the regulator.